Humana Inc. (HUM) incurred a fourth-quarter 2024 adjusted net loss of $2.16 per share, narrower than the Zacks Consensus Estimate of a loss of $2.26 per share but wider than the prior-year quarter’s loss of 11 cents per share.See the Zacks Earnings Calendar to stay ahead of market-making news.Adjusted revenues of $29.2 billion advanced 13.5% year over year. The top line surpassed the consensus mark by 1.1%. The quarterly results were hurt by a decline in medical membership, which in turn, resulted from a ye ...

Financial Data and Key Metrics Changes - 2024 adjusted EPS is in line with initial guidance, reaffirming the 2025 outlook with a commitment to achieving at least a 3% margin in individual MA [10][11] - Operating expense ratio improved by 40 basis points in 2024, indicating progress in operational efficiency [19] Business Line Data and Key Metrics Changes - Nearly 5% membership growth in 2024, despite repricing products to reflect elevated medical cost trends [14] - Significant improvement in STAR's performance with 650,000 care gaps closed in Q4 2024, aiming for an industry-leading position by 2027 [17][18] Market Data and Key Metrics Changes - The company is experiencing a shift in membership mix towards higher lifetime value segments, particularly in states like Florida, Illinois, and Texas [84] - Medicaid is expected to grow by approximately 175,000 to 150,000 members in 2025, with modest improvements in margin anticipated [112] Company Strategy and Development Direction - Focus on four levers: product experience, clinical excellence, operational efficiency, and capital allocation for growth [13][22] - Emphasis on improving clinical outcomes and reducing system costs to enhance product profitability [16] - Plans to balance margin recovery with prudent balance sheet management while pursuing organic growth and acquisitions [23][24] Management's Comments on Operating Environment and Future Outlook - The healthcare system remains complicated and expensive, with a need for high-quality, affordable care [25][26] - Management acknowledges the challenges posed by regulatory headwinds but remains optimistic about the long-term potential of Medicare Advantage [32][34] Other Important Information - New management team members introduced, including a new CFO with experience in navigating difficult external headwinds [11][12] - The company is committed to evolving its service delivery to be more nimble and responsive to market changes [34] Q&A Session Summary Question: 2025 MLR guidance breakdown - The majority of improvement in the MLR ratio is driven by MA plan exits with high benefit ratios, alongside adjustments in remaining plans [43][44] Question: 2026 outlook and core business growth - The company does not typically provide guidance for 2026 due to uncertainties, focusing instead on improving operating performance [50][52] Question: Path to 3% margins - Achieving a 3% margin requires a competitive stars position, normalized rate environment, and optimal operating performance [55][56] Question: Investments impacting earnings growth - Incremental investments are aimed at improving operating performance, particularly in STARS and clinical excellence [65] Question: D SNP attrition and guidance impact - The company experienced higher than expected D SNP attrition but is learning from this to inform future strategies [86][88] Question: Part D seasonality expectations - The company expects growth in Part D membership due to competitive dynamics and pricing strategies [92][94] Question: Medicaid margin trajectory - Medicaid margins are expected to improve modestly in 2025, with ongoing maturation in states with less experience [113][115] Question: Specialty RX trends - Specialty drug spend remains elevated but stable, aligning with pricing expectations [117] Question: Group MA margin pressure - The group product is experiencing margin pressure due to evolving industry dynamics, with expectations for improvement in 2026 [136]

Key TakeawaysHumana expects Medicare Advantage members to decline in 2025, following a downgrade to the quality rating of one of its biggest plans.The health insurer reported fourth-quarter revenue that exceeded expectations and a narrower-than-expected adjusted loss.Humana shares have lost more than a quarter of their value over the past 12 months. Humana (HUM) shares slid after the health insurer said it expects Medicare Advantage memberships to decline in 2025. The health insurer reported fourth-quarter ...

Humana (HUM) reported $29.12 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 13.2%. EPS of -$2.16 for the same period compares to -$0.11 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $28.82 billion, representing a surprise of +1.05%. The company delivered an EPS surprise of +4.42%, with the consensus EPS estimate being -$2.26.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall St ...

SAN DIEGO, Feb. 11, 2025 /PRNewswire/ -- The Shareholders Foundation, Inc. announced an update in the lawsuit that is pending for certain investors in shares of Humana Inc. (NYSE: HUM).Investors who purchased shares of Humana Inc. (NYSE: HUM) prior to July 2022 and continue to hold any of thoseNYSE: HUM shares have also certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.In June 2024, an investor inNYSE: HUM shares filed a lawsuit against Humana Inc ...

Humana Tuesday reported $1.2 billion in 2024 profits that included a $693 million fourth quarter ... [+] loss as the health insurer exits unprofitable Medicare Advantage markets for 2025, the company disclosed Feb. 11, 2025. In this photo is a Humana office in Louisville, Kentucky, US, on Monday, July 31, 2023. (Photographer: Jon Cherry/Bloomberg)© 2023 Bloomberg Finance LPHumana Tuesday reported $1.2 billion in 2024 profits that included a $693 million fourth quarter loss as the health insurer exits unprof ...

Health insurance company Humana HUM is set to release its fourth-quarter 2024 earnings report on Feb. 11, before market hours. The stock has dropped 2.37% from the previous close, as of writing, on Feb.10, according to Benzinga Pro. The stock is up 5.58% year-to-date but has fallen 27.73% in the past year.In the previous quarter, Humana reported revenues of $29.4 billion — a 15.2% year-over-year increase. It surpassed analysts’ expectations by 2.6%. The company also achieved a solid beat on earnings per sha ...

Humana Inc. (HUM) is scheduled to release fourth-quarter 2024 results on Feb. 11, before the opening bell. The Zacks Consensus Estimate for earnings is pegged at a loss of $2.26 per share, wider than the prior-year quarter’s loss of 11 cents per share.  See the Zacks Earnings Calendar to stay ahead of market-making news.The fourth-quarter earnings estimate has witnessed one downward revision over the past 30 days. Meanwhile, the Zacks Consensus Estimate for revenues is pegged at $28.8 billion, indicating 12 ...

Analysts on Wall Street project that Humana (HUM) will announce quarterly loss of $2.26 per share in its forthcoming report, representing a decline of 1954.6% year over year. Revenues are projected to reach $28.82 billion, increasing 12% from the same quarter last year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.7% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Before ...

New York, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Sword Health, an AI health company making world-class, life-changing care accessible anytime, anywhere, today announced the appointment of Bruce Broussard, former CEO of Humana, as a board advisor. Broussard’s extensive experience in healthcare innovation and leadership further strengthens Sword Health’s mission to free the world from pain.  “Bruce’s visionary leadership and unwavering commitment to advancing healthcare accessibility and outcomes make him an inva ...